
CRISPR Therapeutics AG
CRSPHealthcare|Biotechnology|CH
$50.07
+1.51 (+3.11%)
Tangible Book / Share
$17.04
Cash / Share
$23.49
Financials
Financial Snapshot
Market Cap
$4.86B
Enterprise Value
$5.44B
Revenue (TTM)
$25.2M
Net Income (TTM)
-$456.1M
Cash & Investments
$2.27B
Net Cash
$1.49B
Free Cash Flow (TTM)
-$379.2M
Operating CF (TTM)
-$374.6M
Debt/Equity
0.47
Cash Runway & Burn Rate
Cash on Hand
$2.27B
Quarterly Burn
$93.7M
Monthly Burn
$31.2M
Est. Runway
~24.3 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $315.5M | $239.8M | $456.6M | $943.8M | $1.69B | $2.38B | $1.82B | $1.69B | $1.90B | $1.98B | $2.27B | |
| Operating Cash Flow | -$55.3M | -$70.1M | -$96.2M | $56.7M | -$238.4M | $539.0M | -$495.7M | -$260.4M | -$142.8M | -$345.0M | -$374.6M | |
| Free Cash Flow | -$58.3M | -$77.9M | -$99.0M | $50.0M | -$256.7M | $457.3M | -$532.9M | -$269.8M | -$144.7M | -$345.9M | -$379.2M | |
| Capital Expenditure | -$3.0M | -$7.8M | -$2.8M | -$6.7M | -$18.4M | -$81.7M | -$37.2M | -$9.5M | -$1.9M | -$914.0K | -$4.6M | |
| Financing Cash Flow | $183.2M | $2.6M | $315.9M | $431.0M | $1.02B | $250.9M | $38.6M | $62.7M | $332.0M | $426.0M | $720.0M |
R&D Spending
R&D (TTM)
$283.3M
R&D Intensity
1125.4%
R&D Growth vs Prior
+6.8%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $41.0M | $3.1M | $289.6M | $719.0K | $913.1M | $436.0K | $370.0M | $35.0M | $3.5M | $25.2M | |
| R&D Expense | $42.2M | $69.8M | $113.8M | $179.4M | $221.4M | $340.6M | $461.6M | $387.3M | $320.7M | $265.3M | $283.3M | |
| R&D % of Revenue | 817.9% | 170.3% | 3641.9% | 61.9% | 30790.3% | 37.3% | 105881.9% | 104.7% | 916.2% | 7559.2% | 1125.4% | |
| SG&A | $31.1M | $35.8M | $48.3M | $63.5M | $85.7M | $99.7M | $102.5M | $76.2M | $73.0M | $73.5M | $68.9M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $41.0M | $3.1M | $289.6M | $719.0K | $913.1M | $436.0K | $370.0M | $35.0M | $3.5M | $25.2M | |
| Cost of Revenue | $42.2M | $69.8M | $113.8M | $179.4M | $269.4M | $101.2M | $110.3M | $130.3M | $110.3M | $233.0M | $195.5M | |
| Gross Profit | -$37.1M | -$28.8M | -$110.6M | $110.2M | -$268.7M | $811.9M | -$109.8M | $239.8M | -$75.3M | -$229.4M | -$170.3M | |
| R&D | $42.2M | $69.8M | $113.8M | $179.4M | $221.4M | $340.6M | $461.6M | $387.3M | $320.7M | $265.3M | $283.3M | |
| SG&A | $31.1M | $35.8M | $48.3M | $63.5M | $85.7M | $99.7M | $102.5M | $76.2M | $73.0M | $73.5M | $68.9M | |
| Operating Income | -$68.1M | -$64.6M | -$158.9M | $46.7M | -$354.4M | $373.5M | -$673.2M | -$222.5M | -$466.6M | -$568.3M | -$529.9M | |
| Interest Expense | $8.1M | $0.00 | $0.00 | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$22.7M | -$66.6M | -$164.4M | $67.3M | -$348.1M | $379.5M | -$650.5M | -$150.7M | -$362.7M | -$578.0M | -$453.6M | |
| Net Income | -$23.2M | -$68.4M | -$165.0M | $66.9M | -$348.9M | $377.7M | -$650.2M | -$153.6M | -$366.3M | -$581.6M | -$456.1M | |
| EPS (Diluted) | -1.89 | -1.71 | -3.44 | 1.17 | -5.29 | 4.70 | -8.36 | -1.94 | -4.34 | -6.47 | -4.74 | |
| EBITDA | -$13.7M | -$61.6M | -$155.4M | $51.5M | -$345.3M | $397.5M | -$626.3M | -$130.9M | -$343.4M | -$558.5M | -$459.8M | |
| Shares Out. (M) | 12.26 | 40.06 | 47.96 | 56.93 | 65.95 | 80.39 | 77.75 | 79.22 | 84.36 | 89.93 | 96.74 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $315.5M | $239.8M | $456.6M | $943.8M | $1.17B | $923.0M | $211.9M | $389.5M | $298.3M | $355.2M | $192.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $521.7M | $1.46B | $1.60B | $1.30B | $1.61B | $1.63B | $2.08B | |
| Total Current Assets | $320.2M | $248.4M | $466.4M | $987.5M | $1.72B | $2.42B | $1.85B | $1.91B | $1.94B | $1.99B | $2.29B | |
| Total Assets | $345.0M | $271.3M | $489.0M | $1.07B | $1.83B | $2.75B | $2.24B | $2.23B | $2.24B | $2.27B | $2.56B | |
| Total Current Liabilities | $22.0M | $14.5M | $27.7M | $57.1M | $94.3M | $119.9M | $121.1M | $108.8M | $87.8M | $149.1M | $141.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $188.2M | $586.9M | |
| Total Liabilities | $112.1M | $83.5M | $96.8M | $127.3M | $163.7M | $352.4M | $367.6M | $346.8M | $310.0M | $343.4M | $908.3M | |
| Stockholders' Equity | $232.8M | $187.8M | $392.2M | $939.4M | $1.66B | $2.40B | $1.88B | $1.88B | $1.93B | $1.92B | $1.65B | |
| Retained Earnings | -$57.1M | -$125.4M | -$291.6M | -$224.7M | -$573.6M | -$195.9M | -$846.1M | -$999.7M | -$1.37B | -$1.95B | -$2.27B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$55.3M | -$70.1M | -$96.2M | $56.7M | -$238.4M | $539.0M | -$495.7M | -$260.4M | -$142.8M | -$345.0M | -$374.6M | |
| Capital Expenditure | -$3.0M | -$7.8M | -$2.8M | -$6.7M | -$18.4M | -$81.7M | -$37.2M | -$9.5M | -$1.9M | -$914.0K | -$4.6M | |
| Free Cash Flow | -$58.3M | -$77.9M | -$99.0M | $50.0M | -$256.7M | $457.3M | -$532.9M | -$269.8M | -$144.7M | -$345.9M | -$379.2M | |
| Investing Cash Flow | $31.9M | -$8.3M | -$2.8M | $1.3M | -$541.2M | -$1.04B | -$258.7M | $374.6M | -$280.5M | -$31.8M | -$443.3M | |
| Financing Cash Flow | $183.2M | $2.6M | $315.9M | $431.0M | $1.02B | $250.9M | $38.6M | $62.7M | $332.0M | $426.0M | $720.0M | |
| Issuance of Stock | $89.1M | $2.6M | $307.1M | $415.0M | $982.3M | $213.3M | $970.0K | $62.7M | $300.7M | $426.0M | $721.1M | |
| Repurchase of Stock | $0.00 | $0.00 | -$57.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $35.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $10.8M | $18.9M | $35.0M | $44.1M | $66.0M | $102.4M | $97.9M | $81.0M | $86.6M | $72.5M | $69.7M | |
| Net Change in Cash | $159.6M | -$75.8M | $216.9M | $489.0M | $236.7M | -$245.5M | -$715.9M | $177.6M | -$91.3M | $49.3M | -$101.7M |
Dilution Tracker
Shares outstanding grew 36.4% over 5 years — significant dilution
Shares Outstanding
97M
5-Year Share Growth
+36.4%
Stock Issuance (TTM)
$721.1M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 12.26 | 40.06 | 47.96 | 56.93 | 65.95 | 80.39 | 77.75 | 79.22 | 84.36 | 89.93 | 96.74 | |
| Change vs Prior % | — | 226.8% | 19.7% | 18.7% | 15.8% | 21.9% | -3.3% | 1.9% | 6.5% | 6.6% | 7.6% | |
| Stock Issuance | $89.1M | $2.6M | $307.1M | $415.0M | $982.3M | $213.3M | $970.0K | $62.7M | $300.7M | $426.0M | $721.1M | |
| Stock Repurchase | $0.00 | $0.00 | -$57.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $10.8M | $18.9M | $35.0M | $44.1M | $66.0M | $102.4M | $97.9M | $81.0M | $86.6M | $72.5M | $69.7M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -717.9% | -70.3% | -3541.9% | 38.1% | -37369.7% | 88.9% | -25186.7% | 64.8% | -215.0% | -6537.0% | -676.5% | |
| Operating Margin % | -1319.3% | -157.7% | -5087.8% | 16.1% | -49295.5% | 40.9% | -154394.7% | -60.1% | -1333.0% | -16191.4% | -2104.9% | |
| Net Margin % | -449.3% | -166.7% | -5281.1% | 23.1% | -48520.9% | 41.4% | -149122.7% | -41.5% | -1046.4% | -16569.8% | -1812.1% | |
| EBITDA Margin % | -266.1% | -150.3% | -4975.2% | 17.8% | -48018.2% | 43.5% | -143653.2% | -35.4% | -981.2% | -15911.3% | -1826.4% | |
| FCF Margin % | -1129.5% | -190.0% | -3169.4% | 17.3% | -35705.7% | 50.1% | -122231.4% | -72.9% | -413.4% | -9855.5% | -1506.4% | |
| ROE % | -10.0% | -36.4% | -42.1% | 7.1% | -21.0% | 15.7% | -34.7% | -8.2% | -19.0% | -30.3% | -25.6% | |
| ROA % | -6.7% | -25.2% | -33.7% | 6.3% | -19.1% | 13.7% | -29.0% | -6.9% | -16.3% | -25.7% | -17.8% | |
| ROIC % | -21.1% | -25.2% | -34.5% | 4.6% | -20.3% | 14.1% | -31.5% | -10.4% | -21.5% | -26.6% | -21.8% | |
| R&D / Revenue % | 817.9% | 170.3% | 3641.9% | 61.9% | 30790.3% | 37.3% | 105881.9% | 104.7% | 916.2% | 7559.2% | 1125.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1990.7% | 693.9% | -92.4% | 9169.8% | -99.8% | 126893.2% | -100.0% | 84762.4% | -90.5% | -90.0% | |
| Gross Profit | -200.8% | 22.3% | -284.2% | 199.6% | -343.8% | 402.2% | -113.5% | 318.3% | -131.4% | -204.9% | |
| Operating Income | -164.8% | 5.1% | -145.9% | 129.4% | -858.3% | 205.4% | -280.2% | 66.9% | -109.7% | -21.8% | |
| Net Income | 10.2% | -194.6% | -141.4% | 140.5% | -621.8% | 208.3% | -272.2% | 76.4% | -138.4% | -58.8% | |
| EPS (Diluted) | -114.8% | 9.5% | -101.2% | 134.0% | -552.1% | 188.8% | -277.9% | 76.8% | -123.7% | -49.1% | |
| Operating Cash Flow | -193.1% | -26.7% | -37.3% | 158.9% | -520.6% | 326.1% | -192.0% | 47.5% | 45.2% | -141.7% | |
| Free Cash Flow | -200.1% | -33.6% | -27.1% | 150.5% | -613.5% | 278.1% | -216.5% | 49.4% | 46.4% | -139.1% | |
| R&D Expense | 235.9% | 65.3% | 63.0% | 57.6% | 23.4% | 53.8% | 35.6% | -16.1% | -17.2% | -17.3% | |
| SG&A Expense | 131.7% | 15.4% | 34.7% | 31.5% | 35.1% | 16.3% | 2.8% | -25.7% | -4.2% | 0.8% | |
| Total Assets | 116.4% | -21.3% | 80.2% | 118.1% | 71.4% | 50.5% | -18.5% | -0.6% | 0.6% | 1.0% | |
| Book Value / Share | 2011.0% | -75.3% | 74.0% | 111.2% | 46.1% | 25.2% | -23.6% | -1.5% | -3.6% | -6.7% | |
| Debt | -100.0% | 0.0% | 0.0% | 0.0% | 16.9% | 266.3% | 8.4% | -2.2% | -6.3% | 76.5% | |
| Diluted Shares | -58.2% | 226.8% | 19.7% | 18.7% | 15.8% | 21.9% | -3.3% | 1.9% | 6.5% | 6.6% |
Valuation
P/E (TTM)At Loss
P/S192.95
10Y Low / Med / High6.30 / 94.87 / 14043.89
P/B2.94
10Y Low / Med / High1.07 / 2.63 / 6.07
EV/EBITDAAt Loss
10Y Low / Med / High4.89 / 12.72 / 47.05
EV/Revenue216.30
10Y Low / Med / High5.54 / 92.74 / 12503.98
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$17.04
Net Current Assets / Share
$14.19
Graham Net-Net
$14.10
Cash / Share
$23.49
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -10.72 | -13.73 | -8.31 | 49.52 | -28.94 | 15.25 | -4.86 | -32.27 | -9.07 | -8.11 | -10.56 | |
| P/S Ratio | 48.09 | 22.89 | 438.61 | 11.44 | 14043.89 | 6.30 | 7248.62 | 13.40 | 94.87 | 1343.50 | 192.95 | |
| P/B Ratio | 1.07 | 5.00 | 3.49 | 3.53 | 6.07 | 2.40 | 1.69 | 2.63 | 1.72 | 2.45 | 2.94 | |
| EV/EBITDA | 4.89 | -11.34 | -5.88 | 47.05 | -26.04 | 12.72 | -5.10 | -36.74 | -9.45 | -8.51 | -11.84 | |
| EV/Revenue | -13.01 | 17.05 | 292.43 | 8.36 | 12503.98 | 5.54 | 7322.33 | 13.00 | 92.74 | 1354.81 | 216.30 |
Analyst Estimates & Quality
Altman Z-Score
2.36
Grey Zone
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $34.2M | $120.0M | $489.8M |
| Net Income | -$441.0M | -$366.4M | -$287.5M |
| EPS | $-4.50 | $-3.55 | $-2.00 |
| # Analysts (EPS) | 13 | 15 | 7 |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Collaborative Arrangement Material Rights | $46.7M | $46.7M | — | — | — | — |
| Duchenne Muscular Dystrophy License | $151.1M | $151.1M | — | — | — | — |
| Myotonic Dystrophy Type One License | $51.3M | $51.3M | — | — | — | — |
| Myotonic Dystrophy Type One R And D Services | $1.1M | $1.1M | — | — | — | — |
| Specified Target Option Material Right | $11.8M | $11.8M | — | — | — | — |
| Exclusive License | — | $900.0M | — | — | — | — |
| Collaborative Arrangement Material Rights Fourth Exclusive License | — | $6.7M | — | — | — | — |
| Collaboration Revenue | — | — | $436.0K | $370.0M | $35.0M | — |
| Grant | — | — | $762.0K | $1.2M | $2.3M | $3.5M |